These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 29067309)

  • 1. Alzheimer's drug-development pipeline: 2016.
    Cummings J; Morstorf T; Lee G
    Alzheimers Dement (N Y); 2016 Nov; 2(4):222-232. PubMed ID: 29067309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alzheimer's disease drug development pipeline: 2017.
    Cummings J; Lee G; Mortsdorf T; Ritter A; Zhong K
    Alzheimers Dement (N Y); 2017 Sep; 3(3):367-384. PubMed ID: 29067343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alzheimer's disease drug development pipeline: 2018.
    Cummings J; Lee G; Ritter A; Zhong K
    Alzheimers Dement (N Y); 2018; 4():195-214. PubMed ID: 29955663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alzheimer's disease drug development pipeline: 2022.
    Cummings J; Lee G; Nahed P; Kambar MEZN; Zhong K; Fonseca J; Taghva K
    Alzheimers Dement (N Y); 2022; 8(1):e12295. PubMed ID: 35516416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alzheimer's disease drug development pipeline: 2019.
    Cummings J; Lee G; Ritter A; Sabbagh M; Zhong K
    Alzheimers Dement (N Y); 2019; 5():272-293. PubMed ID: 31334330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alzheimer's disease drug development pipeline: 2021.
    Cummings J; Lee G; Zhong K; Fonseca J; Taghva K
    Alzheimers Dement (N Y); 2021; 7(1):e12179. PubMed ID: 34095440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alzheimer's disease drug development pipeline: 2020.
    Cummings J; Lee G; Ritter A; Sabbagh M; Zhong K
    Alzheimers Dement (N Y); 2020; 6(1):e12050. PubMed ID: 32695874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alzheimer's disease drug development pipeline: 2023.
    Cummings J; Zhou Y; Lee G; Zhong K; Fonseca J; Cheng F
    Alzheimers Dement (N Y); 2023; 9(2):e12385. PubMed ID: 37251912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Current Clinical Trials in the Treatment of Alzheimer's Disease].
    Tamaoka A
    Brain Nerve; 2020 Jan; 72(1):23-34. PubMed ID: 31907330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Trials for Disease-Modifying Therapies in Alzheimer's Disease: A Primer, Lessons Learned, and a Blueprint for the Future.
    Cummings J; Ritter A; Zhong K
    J Alzheimers Dis; 2018; 64(s1):S3-S22. PubMed ID: 29562511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Not Available].
    Cummings J; Zhou Y; Lee G; Zhong K; Fonseca J; Cheng F
    Alzheimers Dement (N Y); 2024; 10(2):e12465. PubMed ID: 38659717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alzheimer's disease drug-development pipeline: few candidates, frequent failures.
    Cummings JL; Morstorf T; Zhong K
    Alzheimers Res Ther; 2014; 6(4):37. PubMed ID: 25024750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer's disease.
    Ruthirakuhan M; Herrmann N; Suridjan I; Abraham EH; Farber I; Lanctôt KL
    Expert Opin Pharmacother; 2016 Dec; 17(18):2417-2429. PubMed ID: 27825018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacotherapy for Alzheimer's disease: what's new on the horizon?
    Khoury R; Gallop A; Roberts K; Grysman N; Lu J; Grossberg GT
    Expert Opin Pharmacother; 2022 Aug; 23(11):1305-1323. PubMed ID: 35793398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repurposed agents in the Alzheimer's disease drug development pipeline.
    Bauzon J; Lee G; Cummings J
    Alzheimers Res Ther; 2020 Aug; 12(1):98. PubMed ID: 32807237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging treatments for Alzheimer's disease for non-amyloid and non-tau targets.
    Khan A; Corbett A; Ballard C
    Expert Rev Neurother; 2017 Jul; 17(7):683-695. PubMed ID: 28490260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On the horizon-the value and promise of the global pipeline of Alzheimer's disease therapeutics.
    Cole MA; Seabrook GR
    Alzheimers Dement (N Y); 2020; 6(1):e12009. PubMed ID: 32405530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of basket trials in drug development for neurodegenerative disorders.
    Cummings J; Montes A; Kamboj S; Cacho JF
    Alzheimers Res Ther; 2022 May; 14(1):73. PubMed ID: 35614479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends.
    Bachurin SO; Bovina EV; Ustyugov AA
    Med Res Rev; 2017 Sep; 37(5):1186-1225. PubMed ID: 28084618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-Tau Trials for Alzheimer's Disease: A Report from the EU/US/CTAD Task Force.
    Cummings J; Blennow K; Johnson K; Keeley M; Bateman RJ; Molinuevo JL; Touchon J; Aisen P; Vellas B
    J Prev Alzheimers Dis; 2019; 6(3):157-163. PubMed ID: 31062825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.